|
US4275149A
(en)
|
1978-11-24 |
1981-06-23 |
Syva Company |
Macromolecular environment control in specific receptor assays
|
|
US4318980A
(en)
|
1978-04-10 |
1982-03-09 |
Miles Laboratories, Inc. |
Heterogenous specific binding assay employing a cycling reactant as label
|
|
US4424200A
(en)
|
1979-05-14 |
1984-01-03 |
Nuc Med Inc. |
Method for radiolabeling proteins with technetium-99m
|
|
US4479930A
(en)
|
1982-07-26 |
1984-10-30 |
Trustees Of The University Of Massachusetts |
Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
|
|
GB8308235D0
(en)
|
1983-03-25 |
1983-05-05 |
Celltech Ltd |
Polypeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
JPS61134325A
(ja)
|
1984-12-04 |
1986-06-21 |
Teijin Ltd |
ハイブリツド抗体遺伝子の発現方法
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4987071A
(en)
|
1986-12-03 |
1991-01-22 |
University Patents, Inc. |
RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
|
|
US5185243A
(en)
|
1988-08-25 |
1993-02-09 |
Syntex (U.S.A.) Inc. |
Method for detection of specific nucleic acid sequences
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
WO1993011161A1
(en)
|
1991-11-25 |
1993-06-10 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5837242A
(en)
|
1992-12-04 |
1998-11-17 |
Medical Research Council |
Multivalent and multispecific binding proteins, their manufacture and use
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
GB9509957D0
(en)
|
1995-05-17 |
1995-07-12 |
Khalil Nasreen |
Post-translational activation of tgf-1 involving the tsp-1 receptor cd36
|
|
US5814468A
(en)
|
1996-03-27 |
1998-09-29 |
Coulter International Corp. |
Methods of enumerating receptor molecules for specific binding partners on formed bodies and in solution
|
|
US5958671A
(en)
|
1996-04-23 |
1999-09-28 |
Presidents And Fellows Of Harvard College |
Methods and compositions for regulating T cell subsets by modulating transcription factor activity
|
|
ES2144386T5
(es)
|
1996-12-23 |
2012-12-07 |
Immunex Corporation |
Ligando para el activador del receptor de NF-kappa b, el ligando es miembro de la superfamilia de TNF
|
|
US6316408B1
(en)
|
1997-04-16 |
2001-11-13 |
Amgen Inc. |
Methods of use for osetoprotegerin binding protein receptors
|
|
US6274338B1
(en)
*
|
1998-02-24 |
2001-08-14 |
President And Fellows Of Harvard College |
Human c-Maf compositions and methods of use thereof
|
|
JP4562286B2
(ja)
|
1998-12-10 |
2010-10-13 |
ブリストル−マイヤーズ スクウィブ カンパニー |
抗体模倣物および他の結合タンパク質のタンパク質骨格
|
|
US6455502B1
(en)
|
1999-03-15 |
2002-09-24 |
Axys Pharmaceuticals, Inc. |
Compounds and compositions as protease inhibitors
|
|
WO2001049288A1
(en)
|
2000-01-06 |
2001-07-12 |
Merck Frosst Canada & Co. |
Novel compounds and compositions as protease inhibitors
|
|
AU2001253079A1
(en)
|
2000-04-03 |
2001-10-15 |
Corixa Corporation |
Methods, compositions and kits for the detection and monitoring of breast cancer
|
|
US7700359B2
(en)
|
2000-06-02 |
2010-04-20 |
Novartis Vaccines And Diagnostics, Inc. |
Gene products differentially expressed in cancerous cells
|
|
JP4212470B2
(ja)
|
2001-06-26 |
2009-01-21 |
アムジェン フレモント インク． |
Ｏｐｇｌへの抗体
|
|
WO2004006955A1
(en)
|
2001-07-12 |
2004-01-22 |
Jefferson Foote |
Super humanized antibodies
|
|
GB0121033D0
(en)
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
|
AR036375A1
(es)
|
2001-08-30 |
2004-09-01 |
Novartis Ag |
Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
|
|
IL162111A0
(en)
|
2001-12-22 |
2005-11-20 |
4Antibody Ag |
Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
|
|
SE0201980D0
(sv)
|
2002-06-24 |
2002-06-24 |
Astrazeneca Ab |
Novel compounds
|
|
AU2003286499A1
(en)
|
2003-10-17 |
2004-06-06 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Interference with c-maf function in multiple myeloma
|
|
US20090048117A1
(en)
|
2003-12-18 |
2009-02-19 |
President And Fellows Of Harvard College |
Modulation of immune system function by modulation of polypeptide arginine methyltransferases
|
|
US9134237B2
(en)
|
2005-09-20 |
2015-09-15 |
Janssen Diagnotics, LLC |
High sensitivity multiparameter method for rare event analysis in a biological sample
|
|
WO2007053245A2
(en)
|
2005-09-20 |
2007-05-10 |
Immunivest Corporation |
Methods and composition to generate unique sequence dna probes, iabeling of dna probes and the use of these probes
|
|
EP1777523A1
(en)
|
2005-10-19 |
2007-04-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
|
|
ATE552505T1
(de)
|
2006-06-30 |
2012-04-15 |
Univ Southern California |
Quantifizierbare interne referenzstandards für immunhistochemie und verwendung
|
|
WO2008086800A2
(en)
|
2007-01-15 |
2008-07-24 |
Aarhus Universitet |
Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16
|
|
WO2008098351A1
(en)
|
2007-02-14 |
2008-08-21 |
University Health Network |
Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
|
|
CA2676791A1
(en)
|
2007-02-16 |
2008-11-06 |
Pacific Arrow Limited |
Blocking the migration or metastasis of cancer cells by affecting adhesion proteins and the uses of new compounds thereof
|
|
WO2008142164A2
(en)
|
2007-05-24 |
2008-11-27 |
Ablynx N.V. |
Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
|
|
US20110166838A1
(en)
|
2008-06-16 |
2011-07-07 |
Sividon Diagnostics |
Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
|
|
EP2412825B8
(en)
|
2009-03-24 |
2018-01-10 |
Riken |
Leukemia stem cell markers
|
|
WO2011039734A2
(en)
|
2009-10-02 |
2011-04-07 |
Enzo Medico |
Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
|
|
CN108192972B
(zh)
|
2010-10-06 |
2022-09-09 |
生物医学研究机构基金会 |
用于乳腺癌转移的诊断、预后和治疗的方法
|
|
CA2826657A1
(en)
|
2011-02-04 |
2012-08-09 |
Bioarray Therapeutics, Inc. |
Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
|
|
EP2650682A1
(en)
|
2012-04-09 |
2013-10-16 |
Fundació Privada Institut de Recerca Biomèdica |
Method for the prognosis and treatment of cancer metastasis
|
|
EP2859120B1
(en)
*
|
2012-06-06 |
2018-11-14 |
Fundació Institut de Recerca Biomèdica (IRB Barcelona) |
Method for the diagnosis and prognosis of lung cancer metastasis
|
|
ES2744244T3
(es)
|
2012-10-12 |
2020-02-24 |
Inbiomotion Sl |
Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF
|
|
US10119171B2
(en)
|
2012-10-12 |
2018-11-06 |
Inbiomotion S.L. |
Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
|
|
KR20150122786A
(ko)
|
2013-03-15 |
2015-11-02 |
펀다시오 인스티튜트 드 르세르카 바이오메디카 (아이알비 바르셀로나) |
암 전이의 진단, 예후 및 치료를 위한 방법
|
|
US20160032399A1
(en)
|
2013-03-15 |
2016-02-04 |
Inbiomotion S.L. |
Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis
|
|
CA2906394A1
(en)
|
2013-03-15 |
2014-09-18 |
Fundacio Institut De Recerca Biomedica (Irb Barcelona) |
Method for the prognosis and treatment of cancer metastasis
|
|
CN105980576B
(zh)
|
2013-10-09 |
2021-07-16 |
生物医学研究机构基金会 |
用于源自乳腺癌的骨转移癌的预后和治疗的方法
|
|
WO2016092524A1
(en)
|
2014-12-11 |
2016-06-16 |
Inbiomotion S.L. |
Binding members for human c-maf
|
|
KR102571924B1
(ko)
|
2016-05-25 |
2023-08-28 |
인바이오모션 에스.엘. |
c-MAF 상태에 기초한 유방암의 치료
|
|
CN111565725A
(zh)
|
2017-11-22 |
2020-08-21 |
生物运动有限公司 |
基于c-maf状态的乳腺癌的治疗性处理
|